U.S. Markets closed

GSK plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
1,439.60+12.20 (+0.85%)
At close: 06:45PM GMT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1,427.40
Bid1,410.00 x 0
Ask1,495.00 x 0
Day's Range1,416.40 - 1,451.60
52 Week Range1,280.92 - 2,746.59
Avg. Volume10,537,547
Market Cap59.098B
Beta (5Y Monthly)0.29
PE Ratio (TTM)13.82
EPS (TTM)104.20
Earnings DateFeb 01, 2023
Forward Dividend & Yield0.86 (6.18%)
Ex-Dividend DateAug 18, 2022
1y Target EstN/A
  • Insider Monkey

    GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript

    GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript February 1, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the analyst call of GSK Fourth Quarter 2020 Results. I will now hand you over to Nick Stone, Head of Global Investor Relations, who will introduce today’s session. Nick Stone: Thank you, operator. Hello, everyone. […]

  • Zacks

    GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

    GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

  • Reuters

    UPDATE 2-U.S. FDA approves GSK's anemia drug for patients on dialysis

    The U.S. Food and Drug Administration (FDA) on Wednesday approved GSK Plc's drug as the first oral treatment for anemia caused by chronic kidney disease in adults who have been on dialysis for at least four months. The drug Jesduvroq comes with the boxed warning for increased thrombotic vascular events, including death, heart attack, stroke, and blood clots in the lungs, legs, or dialysis access site. The warnings and precautions also include a risk of hospitalization for heart failure, worsening increase of blood pressure, stomach erosions, and gastrointestinal bleeding.